In the midst of a global pandemic, eighteen clinical sites pressed forward with three consecutive early-phase studies of a novel Alzheimer's treatment — a program already stretched thin by compressed timelines and the inherent complexity of multi-site coordination. What might have unraveled instead held together, not through technological innovation or expanded resources, but through the oldest of remedies: direct human communication. By stripping away layers of intermediaries and choosing conversation over bureaucracy, the sponsor and sites completed all three studies on time and within budge